Drug Development
Recursion Pharmaceuticals’ AI-Driven Drug Development Strategy Fails to Impress Investors
Recursion Pharmaceuticals, AI, drug development, investors, biotech, pharmaceuticals
Women Breaking Barriers in Drug Development: Celebrating Leadership and Innovation
Women in drug development, gender equity, STEM, pharmaceutical industry, leadership, innovation
Pfizer and Flagship’s Quotient Therapeutics Collaborate to Identify Novel Targets for Cardiovascular and Renal Diseases
Pfizer, Flagship Pioneering, Quotient Therapeutics, cardiovascular diseases, renal diseases, somatic genomics, drug development, partnership
Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs
Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development
Rafael Holdings and Cyclo Therapeutics Merge to Accelerate Development of Niemann-Pick Disease Type C1 Treatment
Rafael Holdings, Cyclo Therapeutics, merger, Niemann-Pick Disease Type C1, Trappsol Cyclo, clinical trial, pharmaceutical development
Metagenomi Halts ALS Research Following Biogen and Ionis Setbacks
Metagenomi, ALS program, Biogen, Ionis, pharmaceutical industry, drug development, layoffs, market challenges
23andMe Shifts Focus to GLP-1 Telehealth Offering, Cuts Internal Drug Development Team
23andMe, GLP-1, telehealth, weight loss, drug development, layoffs
Exelixis Abandons Tissue Factor-Targeting ADC Due to Competition from Tivdak
Exelixis, tissue factor-targeting ADC, Tivdak, biotech, pharmaceuticals, drug development
Roche Accelerates Obesity Drug Development and Explores M&A Opportunities
Roche, obesity drugs, M&A, pharmaceuticals, drug development
Pinetree Therapeutics Secures $17M in Funding to Advance Targeted Protein Degraders
Pinetree Therapeutics, targeted protein degraders, TPD, Series A funding, pharmaceutical development